Evidence map›Paper›PMID 41054629›Full record

ArticleRespirology case reports2025

Pembrolizumab-Induced Chronic Rhinosinusitis in a Patient With Non-Small Cell Lung Cancer.

Yuji Yamasaki, Hiroshi Ohnishi, Masahiro Komori, Junya Mizuta, Mitsuko Iguchi, Akihito Yokoyama

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Respirology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuji YamasakiDepartment of Respiratory Medicine and Allergology Kochi Medical School, Kochi University Nankoku Japan.ORCID https://orcid.org/0009-0005-4533-4164
Hiroshi OhnishiDepartment of Respiratory Medicine and Allergology Kochi Medical School, Kochi University Nankoku Japan.
Masahiro KomoriDepartment of Otolaryngology, Head and Neck Surgery Kochi Medical School, Kochi University Nankoku Japan.
Junya MizutaDepartment of Respiratory Medicine and Allergology Kochi Medical School, Kochi University Nankoku Japan.
Mitsuko IguchiDepartment of Diagnostic Pathology, Kochi Medical School Kochi University Nankoku Japan.
Akihito YokoyamaDepartment of Respiratory Medicine and Allergology Kochi Medical School, Kochi University Nankoku Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 63-year-old man was administered pembrolizumab for stage IV squamous cell lung cancer. After 54 cycles of pembrolizumab, the patient maintained complete remission of lung cancer but developed nasal obstruction, olfactory disturbance, conjunctivitis, stomatitis, glossitis, pharyngitis, and weight loss. Laboratory data showed increased levels of neutrophils, eosinophils, C-reactive protein, squamous cell carcinoma antigen, and cytokeratin 19 fragments. Sinus computed tomography revealed obstruction of the maxillary, ethmoid, and sphenoidal sinuses. Histological examination of nasal septal tissue revealed chronic rhinosinusitis with infiltration primarily of eosinophils, neutrophils, CD3

Indexed as

chronic rhinosinusitisimmune checkpoint inhibitorimmune‐related adverse eventnon‐small cell lung cancerpembrolizumab

Identifiers

PMID41054629
PMCPMC12497504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.